Evaluating risk-based allocation strategies for PCSK9 inhibitors: results from a simulation study in a contemporary ASCVD cohort

Back

ESC Professional Premium Access

Evaluating risk-based allocation strategies for PCSK9 inhibitors: results from a simulation study in a contemporary ASCVD cohort

Session: Risk factors and prevention: lipids (2)

Topic: Drug therapy

Speaker: Doctor C. Blaum (Hamburg, DE)

Event: ESC Congress 2023

Congress Presentation

Add to my library

About the speaker

Doctor Christopher Blaum

University Heart and Vascular Centre Hamburg (UHZ), Hamburg (Germany)

1 presentation

0 follower

8 more presentations in this session

Hyperlipoproteinemia(a) in coronary artery disease patients: who are patients with very high levels and how do they respond to the PCSK9 antibody therapy?

Speaker: Doctor M. Novakovic (Ljubljana, SI)

Prevalence and outcomes of familial hypercholesterolemia in young patients undergoing coronary bypass surgery

Speaker: Doctor J. Black (Hobart, AU)

Increased triglyceride independently associates with premature structural and functional cardiac damage progression in asymptomatic adolescents: a 7-year longitudinal study

Speaker: Doctor A. Agbaje (Kuopio, FI)

Characterization of lipidic coronary atheroma under control of low-density lipoprotein <1.8 mmol/l and lipoprotein (a) <50 mg/dl in patients with coronary artery disease

Speaker: Doctor D. Shishikura (Takatsuki, JP)

Increased Lipoprotein (a) and familial hypercholesterolemia: a dangerous combination.Data from a 12-year follow-up study

Speaker: Doctor I. Andrikou (Athens, GR)

Access the full session

Risk factors and prevention: lipids (2)

Speakers: Doctor C. Blaum, Doctor M. Novakovic, Doctor J. Black, Doctor A. Agbaje, Doctor D. Shishikura...

Access

About the event

ESC Congress 2023

25 August - 28 August 2023

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources